Bioventus Q1 Revenue Rises 7% to $132.1M with $3.1M Profit
Bioventus reported Q1 revenue of $132.1M, up 7%, and net income of $3.1M (GAAP EPS $0.04, non-GAAP EPS $0.15) reversing last year’s loss. The company increased full-year adjusted EPS guidance to $0.75–$0.79 and plans a $22M debt prepayment, boosting cash flow targets to $84–$89M.
1. Q1 Financial Results
Bioventus posted Q1 revenue of $132.1M, a 7% increase year-over-year, delivering net income of $3.1M compared with a $2.6M loss in the prior year. GAAP earnings totaled $0.04 per share and non-GAAP earnings reached $0.15 per share, up from $0.08 in the year-ago period.
2. Segment Performance
Revenue across Pain Treatments rose 7.7% to $63.4M on favorable rebate benefits and stable demand, Surgical Solutions grew 6.2% to $48.0M driven by higher U.S. Bone Graft Substitutes and Ultrasonics sales, and Restorative Therapies climbed 4.6% to $20.6M supported by EXOGEN Bone Stimulation System adoption.
3. Guidance and Financial Actions
The company made a $22.0M discretionary principal prepayment on its term loan to lower future interest costs and improve financial metrics. It raised full-year adjusted EPS guidance to $0.75–$0.79 and cash from operations expectations to $84M–$89M, while reaffirming revenue guidance of $600M–$610M.